LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Drug resistance to targeted therapies like tyrosine kinase inhibitors (TKIs) is a major challenge in cancer treatment.
• Mechanisms underlying TKI resistance, particularly in EGFR-mutant non-small cell lung cancer (NSCLC), are not fully understood.

Purpose of the Study:

• To identify novel factors contributing to gefitinib resistance in EGFR-mutant NSCLC.
• To elucidate the molecular pathways through which these factors mediate resistance.
• To explore potential therapeutic strategies to overcome TKI resistance.

Main Methods:

• Utilized EGFR-mutant NSCLC cell lines (HCC827 and H1650) with varying gefitinib sensitivity.
• Investigated the role of Lipin1 (LPIN1) in gefitinib resistance.
• Assessed diacylglycerol levels, protein kinase C delta and nuclear factor kappa B (NF-κB) activation.
• Analyzed lipid droplet production and its association with TKI resistance.
• Performed in vivo tumorigenesis assays with LPIN1 inhibition (shRNA and pharmaceutical).

Main Results:

• LPIN1 expression and diacylglycerol levels were elevated in gefitinib-resistant NSCLC cells.
• LPIN1 mediated the activation of protein kinase C delta and NF-κB, promoting cancer cell survival.
• LPIN1 contributed to increased lipid droplet production, a factor in TKI resistance.
• Inhibition of LPIN1, both genetically and pharmacologically, significantly reduced tumor growth in vivo.
• Gefitinib treatment induced LPIN1 expression and LPIN1-dependent NF-κB activation in tumor tissues.

Conclusions:

• LPIN1 is a key regulator of gefitinib resistance in EGFR-mutant NSCLC.
• LPIN1-dependent pathways, including NF-κB activation and lipid droplet formation, contribute to TKI resistance.
• Co-treatment with TKIs and LPIN1 inhibitors presents a promising strategy to combat TKI resistance in NSCLC patients.